Since smartphones are central to patients’ lives, incorporating them into clinical trials is a logical step toward more reliable and less burdensome electronic patient-reported outcomes (ePRO) collection.
TORONTO (PRWEB) March 18, 2021
While bring-your-own-device (BYOD) has been in use for years, the pandemic has accelerated wider acceptance with the shift toward decentralized clinical trials and the intensified need for robust, patient-centric clinical trial solutions. Since smartphones are central to patients’ lives, incorporating them into clinical trials is a logical step toward more reliable and less burdensome electronic patient-reported outcomes (ePRO) collection.
The benefits of using a scientifically proven, bring your own device (BYOD) or hybrid solution include:
- Increased patient recruitment
- Increased patient retention
- Better patient experience
- Greater compliance
- Higher-quality data
- Lower costs
- Shorter build timelines
With all these benefits of BYOD and the recent technological advances that have taken place, regulatory, logistic, data privacy and security questions remain. What sort of documentation will the FDA require to support BYOD-derived data? Does BYOD adequately protect patient data? Will BYOD work for a global Phase III study?
Join Gena Gough, MBA, PMP Senior Director, Outcome Solutions, Clinical Ink and Willie Muehlhausen, Chief Executive Officer, Safira Clinical Research in a live webinar on Tuesday, April 6, 2021 at 11am EDT (4pm BST/UK) to hear experts address these considerations, as well as help clinical trial sponsors develop a clear path to use BYOD.
For more information, or to register for this event, visit Bring Your Own Device: Why the Future of Clinical Trials Lies in Your Patients’ Hands.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
ABOUT CLINICAL INK
Clinical Ink, a global clinical technology company, offers data certainty from source to submission via our Lunexis™ eSource clinical technology and configurable direct data capture (DDC), eCOA, ePRO, and eConsent modules. This suite of solutions for capturing and integrating electronic data from sites, clinicians, and patients at its source naturally enhances clinical trial workflows. For virtual, traditional, or hybrid trials, Lunexis technology reduces manual labor and provides anytime, anywhere data access, saving resources as your trials progress. For more information, visit http://www.clinicalink.com.